Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2025 Jan;206(1):172-179.
doi: 10.1111/bjh.19812. Epub 2024 Oct 3.

The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries

Massimo Breccia  1 , Simone Celant  2 , Francesca Palandri  3 , Francesco Passamonti  4 , Pier Paolo Olimpieri  2 , Valentina Summa  2 , Annalisa Guarcello  2 , Giuseppe Alberto Palumbo  5 , Fabrizio Pane  6 , Paola Guglielmelli  7 , Paolo Corradini  8 , Pierluigi Russo  2
Affiliations
Multicenter Study

The impact of starting dose on overall survival in myelofibrosis patients treated with ruxolitinib: A prospective real-world study on AIFA monitoring registries

Massimo Breccia et al. Br J Haematol. 2025 Jan.

Abstract

Ruxolitinib is a JAK1/JAK2 inhibitor approved for the treatment of myelofibrosis (MF)-related splenomegaly or symptoms. The recommended starting dose depends on platelet count, regardless of haemoglobin level at baseline. In the recent years, an overall survival (OS) advantage was reported in patients treated with ruxolitinib compared with best available therapy. We analysed a large Italian cohort of 3494 patients identified by Agenzia Italiana del Farmaco (AIFA) monitoring registries. Of them, 2337 (66.9%) started at reduced dose: these patients were older (median age 70 vs. 67), with increased incidence of large splenomegaly (longitudinal diameter 20 vs. 19.1 cm, median volume 1064 cm3 vs. 1016 cm3), with higher IPSS risk (30.9% vs. 26.1%), and worse ECOG score (more than 1 in 14.3% vs. 9.8%). After balancing for baseline characteristics, Kaplan-Meier analysis showed a median OS of 78.2 months (95% CI 65.9-89) for patients who started at full dose and 52.6 (95% CI 49-56.6) months for patients who started with reduced dose (p < 0.001). Group analysis also showed a substantial difference in patients with intermediate-2 and high IPSS risk. The majority of MF patients in real-world analysis started with a reduced dose of ruxolitinib, which is associated with less favourable outcomes.

Keywords: myelofibrosis; overall survival; ruxolitinib; starting dose.

PubMed Disclaimer

References

REFERENCES

    1. Tefferi A. Primary myelofibrosis: 2019 update on diagnosis, risk‐stratification and management. Am J Hematol. 2018;93:1551–1560.
    1. O'Sullivan JM, Harrison CN. Myelofibrosis: clinicopathologic features, prognosis, and management. Clin Adv Hematol Oncol. 2018;16:121–131.
    1. Price GL, Davis KL, Karve S, Pohl G, Walgren RA. Survival patterns in United States (US) Medicare enrollees with non‐CML myeloproliferative neoplasms (MPN). PLoS One. 2014;9:e90299.
    1. Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf ÅR, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population‐based study. J Clin Oncol. 2012;30:2995–3001.
    1. Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009;113:2895–2901.

Publication types

LinkOut - more resources